Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN 9: Semaglutide vs Placebo as Add-on to SGLT-2i in Type 2 Diabetes
NCT03086330Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2017
- Primary completion
- Jul 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03086330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086330.